Clinical Trial Update: Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress [Phase 3]

View source ↗

Summary

This completed Phase 3 randomized, double-blind trial evaluated escitalopram for reducing emotional distress in ENT cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Escitalopram (escitalopram)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: ENT Cancer | Phase 3 | Status: COMPLETED